The global dexmedetomidine hydrochloride injection market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). A dexmedetomidine hydrochloride injection is used for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care unit (ICU). The global dexmedetomidine hydrochloride injection market is growing due to the increasing cases of acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, brain injury, cardiac arrest, pneumonia, and collapsed lungs, among others. The rising usage of ventilator machines in ICUs is directly boosting the growth of dexmedetomidine hydrochloride injection. According to a report by UpToDate, Inc. in March 2022, around 10% – 15% of patients admitted to ICUs have acute respiratory distress syndrome. The incidence of acute respiratory distress syndrome rises with age, which accounts for 16 per 100,000 people among individuals of age 15 to 19 years; to 306 per 100,000 persons among individuals of age 75 to 84 years. The increasing geriatric population is further boosting the growth of the global dexmedetomidine hydrochloride injection market.
(Get 15% Discount on Buying this Report)
A full report of Global Dexmedetomidine Hydrochloride Injection Market is available at: https://orionmarketreports.com/dexmedetomidine-hydrochloride-injection-market/104602/
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-
- In May 2021, Hikma Pharmaceuticals PLC has announced the launch of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 200mcg/50mL & 400mcg/100mL, in the US market for the sedation of initially intubated and mechanically ventilated patients during treatment in an ICU and of non-intubated patients prior to and/or during surgical and other procedures.
- In September 2020, Dr. Reddy’s Laboratories Ltd. received approval from the USFDA for the launch of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, a therapeutic equivalent generic version of Precedex.
- In December 2019, Slayback Pharma LLC announced its final approval and launch of the dexmedetomidine hydrochloride in 0.9% sodium chloride injection in the US market.
- In June 2019, Fresenius Kabi announced the launch and immediate availability of dexmedetomidine hydrochloride in 0.9% sodium chloride injection in the US market, for sedation of non-intubated patients prior to during surgical and other procedures.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Mylan N.V., Fresenius Kabi AG, and AuroMedics Pharma LLC, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Dexmedetomidine Hydrochloride Injection Market Report by Segment
By Application
- Hospital
- Clinics
- Recovery Center
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
